Results 71 to 80 of about 2,105 (188)

“Locked” cancer cells are more sensitive to chemotherapy

open access: yesBioengineering & Translational Medicine, 2019
The treatment of metastatic cancer is a great challenging issue throughout the world. Conventional chemotherapy can kill the cancer cells and, whereas, would exacerbate the metastasis and induce drug resistance.
Yaqi Lyu   +5 more
doaj   +1 more source

Effects of Phospholipase A2 and Metalloproteinase Inhibitors on Skeletal Muscle Regeneration After Myonecrosis Induced by the Venom of Bothrops asper: An Initial Assessment in Mice

open access: yesToxins
Skeletal muscle regeneration is often impaired after acute muscle damage induced by viperid snake venoms, such as that of Bothrops asper, a medically relevant species in Latin America.
Andrés Zamora   +4 more
doaj   +1 more source

Lipid‐Facilitated Opening of the ADAM10 Sheddase Revealed by Enhanced Sampling Simulations

open access: yesAdvanced Science, Volume 13, Issue 19, 2 April 2026.
Phosphatidylserine acts as a lipid trigger to enhance activation of the sheddase ADAM10. By integrating fluorescence spectroscopy assays with enhanced sampling molecular dynamics simulations, this study shows that phosphatidylserine promotes ADAM10 catalytic activity along with expansion of its extracellular domains, enhancing accessibility to scaffold
Adrien Schahl   +7 more
wiley   +1 more source

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

open access: yes, 1998
PURPOSE This phase I study was performed to evaluate the safety and pharmacokinetics of escalating doses of Marimastat (British Biotech, Inc, Oxford, United Kingdom) in patients with advanced malignancies and to determine the phase II recommended dose to
H S Rasmussen   +10 more
core   +1 more source

Targeting angiogenesis for the treatment of advanced melanoma

open access: yesOncology Reviews, 2011
Metastatic melanoma (MM) carries a dismal prognosis, as it is largely resistant to conventional chemotherapy, bio-chemotherapy and immunotherapy. The search for new effective treatments is an unquestionable priority in MM.
Dimitrios J. Bafaloukos, Helena Linardou
doaj   +1 more source

Systematic Proteomic Characterization of EV‐A71‐Infected Mice Identifies Dynamic Molecular Changes and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Time‐resolved multi‐omics of EV‐A71‐infected BALB/c mice uncovered dynamic host responses, revealing rapid neutrophil extracellular traps (NETs) activation as a key event. Screened drugs (kinase inhibitors) suppressed viral replication in vitro and in vivo, suggesting the promise of targeting host phosphorylation networks as a viable antiviral strategy.
Wanjun Peng   +11 more
wiley   +1 more source

Polymeric Nanoparticles for the Diagnosis and Treatment of Snakebite

open access: yesMacromolecular Chemistry and Physics, Volume 227, Issue 1, 15 January 2026.
Snakebite envenomation affects between 1.8 and 5.5 million people annually, many of whom suffer disabilities or even death. Current antivenoms are composed of plasma‐derived antibodies. However, there remains an underexplored opportunity to utilise polymer‐based nanoparticles.
Neil Prabhakar   +2 more
wiley   +1 more source

Novel Matrix Metalloproteinase Inhibitor [18F]Marimastat-Aryltrifluoroborate as a Probe for In vivo Positron Emission Tomography Imaging in Cancer

open access: yes, 2010
Matrix metalloproteinases (MMP), strongly associated pathogenic markers of cancer, have undergone extensive drug development programs. Marimastat, a noncovalent MMP inhibitor, was conjugated with FITC to label cellular metalloproteinase cancer targets in
Ying Li   +13 more
core   +1 more source

The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites

open access: yesToxins, 2019
Snakebite envenoming (SBE) is a priority neglected tropical disease, which kills in excess of 100,000 people per year. Additionally, many millions of survivors also suffer through disabilities and long-term health consequences. The only treatment for SBE,
Harry F. Williams   +6 more
doaj   +1 more source

Mass spectrometry in ocular drug research

open access: yesMass Spectrometry Reviews, Volume 45, Issue 1, Page 37-68, January/February 2026.
Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy